用于评估胶质瘤的QIB动态磁敏感对比MRI定量影像生物标志物概要
QIB动态磁敏感对比MRI委员会发布概要,针对胶质瘤纵向测量中rCBV的可重复性问题,基于组织归一化AUC的个体内变异系数(强化胶质瘤wCV=0.31,正常脑灰质wCV=0.40),定义了95%置信度下判断真实升高或降低的统计学阈值,并阐述依据与合规要求。
要点
- 强化胶质瘤组织归一化AUC升高≥182%或降低≥64%视为95%置信度下真实变化。
- 正常脑灰质组织归一化AUC升高≥399%或降低≥80%视为95%置信度下真实变化。
- 概要聚焦组织归一化AUC(对比剂浓度-时间曲线下面积)的可重复性,而非rCBV本身。
核心结论
- 为纵向DSC MRI测量定义基于统计学的精度声明,以判断组织归一化AUC值的变化是否超出测量变异。
研究设计与样本
- RSNA定量影像生物标志物联盟(QIBA)DSC MRI生物标志物委员会制定的概要,基于既往报道的个体内变异系数(wCV)提出统计学声明,并讨论合规活动及未来更新。
诊断标准与关键数值
- 强化胶质瘤组织归一化AUC的wCV=0.31,较基线升高≥182%提示95%置信度下已发生升高,降低≥64%提示95%置信度下已发生降低。
- 正常脑灰质组织归一化AUC的wCV=0.40,较基线升高≥399%提示95%置信度下已发生升高,降低≥80%提示95%置信度下已发生降低。
临床应用与阅片要点
- 纵向DSC MRI随访中,可依据上述阈值判断组织归一化AUC变化是否超出测量变异。
- 概要聚焦组织归一化AUC的可重复性,rCBV为临床关注的标志物但非概要直接声明的对象。
- 达到上述精度声明需执行概要规定的合规活动。
局限性
- 既往rCBV测量在患者、设备与软件间的量化与可重复性仍是常规或临床试验纵向DSC MRI应用的关键障碍。
- 概要讨论了基于技术进步与临床护理新数据对概要进行潜在更新的内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The dynamic susceptibility contrast (DSC) MRI measures of relative cerebral blood volume (rCBV) play a central role in monitoring therapeutic response and disease progression in patients with gliomas. Previous investigations have demonstrated promise of using rCBV in classifying tumor grade, elucidating tumor viability after therapy, and differentiating pseudoprogression and pseudoresponse. However, the quantification and reproducibility of rCBV measurements across patients, devices, and software remain a critical barrier to routine or clinical trial use of longitudinal DSC MRI in patients with gliomas. To address this limitation, the RSNA DSC MRI Biomarker Committee of the Quantitative Imaging Biomarkers Alliance developed a Profile that defines statistics-based claims for the precision of longitudinal measurements. Although rCBV is the clinical marker of interest, the Profile focused on the reproducibility of the measured quantitative imaging biomarker, which is the area under the contrast agent concentration-time curve (AUC) normalized by the mean value of normal-appearing contralateral white matter tissue (tissue-normalized AUC values). Based on previous reports of within-subject coefficient of variation (wCV) in the tissue-normalized AUC values for enhancing gliomas (wCV = 0.31), an increase of 182% or more with respect to the baseline tissue-normalized AUC value indicates that an increase has occurred with 95% confidence. In contrast, a decrease of 64% or more with respect to baseline suggests that a decrease has occurred with 95% confidence. Similarly, an increase of 399% or more in the tissue-normalized AUC values in normal brain gray matter tissue (wCV = 0.40) suggests that an increase has occurred with 95% confidence, whereas a decrease of 80% or more with respect to baseline suggests that a decrease has occurred with 95% confidence. This article provides the rationale for these claims and the compliance activities needed to achieve these claims. Potential updates to incorporate new data based on advances in technology and clinical care in the Profile are also discussed.
引用
- Shiroishi MS, Erickson BJ, Hu LS, et al. The QIBA Profile for Dynamic Susceptibility Contrast MRI Quantitative Imaging Biomarkers for Assessing Gliomas. Radiology. 2024. PMID: 39656118. doi:10.1148/radiol.232555
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。